To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min xAI files plans for Colossus ...
Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Discov. 23, 656–657; 2024). With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results